

DETECTION OF DELIVERY VECTOR AND THERAPEUTIC TRANSGENE EXPRESSION IN ANY INTACT FIXED TISSUE USING THE RNAscope™ AND BaseScope™ ASSAYS

HIGHLY SENSITIVE & SPECIFIC


The RNAscope™ technology is a highly sensitive and specific RNA *in situ* hybridization (ISH) method for quantitative, tissue-based assessment of gene expression and addressing questions about therapeutic gene delivery vectors biodistribution and transgene expression. With regards to viral vectors such as adeno-associated virus (AAV) and transgene pharmacodynamics and pharmacokinetics, RNAscope™ ISH is an ideal method to:

- Monitor AAV tissue distribution and transgene expression in any animal model or human tissues
- Quantify AAV+ cell number in target and non-target tissues
- Obtain visual information about penetration of AAV from vasculature into the target tissue
- Quantify cell-specific transgene RNA expression over time to assess expression maintenance and transduced cell clonality
 - Distinguish uniform expression versus clonal populations with heterogeneous expression


SINGLE-MOLECULE DETECTION

The BaseScope™ and RNAscope™ assays use proprietary probe design and signal amplification technologies for specific, single-molecule detection of AAV vector DNA and transgene RNA, including the products of codon-optimized transgenes, in intact fixed tissue:


- Specific detection of AAV genomic DNA is achieved with probes targeting AAV inverted terminal repeat (ITR) sequence and anti-sense strand
- Detection of therapeutic transgene RNA without cross-hybridization to endogenous transcripts is achieved using proprietary probe design algorithms
 - A single nucleotide difference is sufficient for differential detection with the BaseScope™ assay



AAV transgene structure and the RNAscope™ or BaseScope™ probe design



Schematic of AAV transgene detection in a cell with the RNAscope™ or BaseScope™ assay



Detection of rAAV in injected striatum (left) and non injected striatum (right) using the RNAscope™ Assay

RUN A PILOT STUDY WITH ACD'S PHARMA ASSAY SERVICES (PAS)

- Expert team running and analyzing more than 10,000 slides per year
- 12 AAV probes designed and in use; additional probes for any AAV genotype and transgene in two weeks
- Four weeks turn-around time from receipt of samples to results for typical projects
- Board-certified pathologist review
- Quantitative image analysis HALO™ Software

THE RNAscope™ ASSAY IN PUBLICATIONS ON GENE THERAPY

Detection of rAAV2/5 DNA in the rat striatum

Grabinski TM, *et al.* PLoS One (2015).

Impact of age and vector construct on viral-mediated gene transfer in rat brain

Polinski NK, *et al.* Mol Ther Methods Clin Dev (2016).

Silencing of the Huntington's disease gene with RNAi using AAV9-mediated delivery of microRNA


Keeler AM, *et al.* J Huntingtons Dis (2016).

Delivery of the secreted protein EPO to the liver via mRNA nanoparticle therapy


DeRosa F, *et al.* Gene Ther (2016).

Silencing of ALS-associated gene SOD1 using microRNA-SOD1 delivered via rAAVrh10 in mice and nonhuman primates


Borel F, *et al.* Hum Gene Ther (2016).



Detection of *Wnt4* (red) and *Procr* (green) in the mouse retina



Detection of the dopaminergic GPCRs *Drd1* (red) and *Drd2* (green) in the striatum of the mouse brain



Detection of *Met* in human liver cancer

Learn more about ACD's Pharma Assay Services (PAS) | acdbio.com/services